Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
IntraBio's oral drug, Aqneursa, becomes the second therapy to get an FDA nod for the treatment of Niemann-Pick disease type C in the past week...
read more
Additions to sites in Cincinnati, Ohio and Bend, Oregon will broaden the company’s early development capabilities...
read more
The FDA has approved Cobenfy, introducing a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors...
read more
Roche's Genentech will acquire a portfolio of next-generation CDK inhibitors from Regor Pharmaceuticals for the treatment of breast cancer...
read more
Pfizer has sold a substantial stake in consumer health care group Haleon, cutting its shareholding in the maker of Centrum vitamins and Advil painkillers from 22.6% to 15%...
read more
IRLAB Therapeutics has shared positive phase 1 data for its once daily oral tablet that the Swedish drugmaker hopes will become become the first treatment for apathy in neurological disorders.
read more
Two patented dietary supplement ingredients from Gateway Health Alliances increased GLP-1 levels, reduced body weight, and improved metabolic biomarkers in a 12-week clinical study.
read more
Colorcon and specialty chemicals provider LOTTE Fine Chemical have inked a multi-year partnership to develop and manufacture pharmaceutical and dietary supplement formulations.
read more
The U.S. FDA says Trinity Gold, a dietary supplement promoted for joint and muscle pain, contains hidden drug ingredients.
read more
Honeywell announced a plan to spin off its Advanced Materials business into an independent, U.S. publicly traded company...
read more
Melt Pharmaceuticals announced the dosing of the last patient in its phase 3 study evaluating its lead product candidate, MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.
read more
Sanofi has entered into negotiations with U.S.-based private equity company CD&R for the potential sale of a 50% controlling stake in Opella, its consumer health care business...
read more
Vanda Pharmaceuticals has received a second unsolicited, non-binding proposal from UK-based Cycle Group to acquire the company and has once again rejected the offer...
read more
CDMO Sirio Pharma has invested approximately $17.4 million in a dedicated packaging facility at its Pritzwalk campus near Berlin...
read more
Catalent has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Belgium CDMO Ardena...
read more